Sector
PharmaceuticalsOpen
₹942.3Prev. Close
₹939.6Turnover(Lac.)
₹163.17Day's High
₹947.4Day's Low
₹936.952 Week's High
₹1,303.952 Week's Low
₹725.2Book Value
₹264.28Face Value
₹2Mkt Cap (₹ Cr.)
18,451.38P/E
37.75EPS
24.87Divi. Yield
1.1718 Apr 2025
12:00 AM
Board Meeting
Agenda : Audited Result
21 Jun 2024
12:00 AM
AGM
Announcement Date: 21 Jun, 2024
EBITDA was up 9% at ₹286 crore, with EBITDA margin at 16% of total sales, reflecting operating efficiency.
The approved product is the generic equivalent of Tegretol Tablets 200 mg, which was initially developed by Novartis Pharmaceuticals Corporation.
This approval bolsters Alembic's portfolio in the United States market and reinforces its presence in injectable segment
Following an inspection carried out from Nov 14-22 2024, the facility was cited as being ‘VAI’ (Voluntary Action Indicated).
EBITDA margin came in at 15.4% in the quarter under review as compared to 16.30% in the previous corresponding period.
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 39.31 | 39.31 | 39.31 | 39.31 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 5,155.43 | 4,869.6 | 4,374.99 | 5,251.03 |
Net Worth | 5,194.74 | 4,908.91 | 4,414.3 | 5,290.34 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 5,051.44 | 4,132.55 | 2,945.26 | 2,985.9 |
yoy growth (%) | 22.23 | 40.31 | -1.36 | -0.76 |
Raw materials | -1,297.91 | -1,045.89 | -892.73 | -886.29 |
As % of sales | 25.69 | 25.3 | 30.31 | 29.68 |
Employee costs | -948.27 | -806.37 | -582.72 | -527.46 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 1,416.6 | 1,176.79 | 535.23 | 549.71 |
Depreciation | -152.6 | -135.67 | -101.76 | -82.9 |
Tax paid | -241.21 | -197.39 | -113.25 | -119.08 |
Working capital | -16.69 | 598.87 | 208.77 | -67.37 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 22.23 | 40.31 | -1.36 | -0.76 |
Op profit growth | 30.7 | 90.16 | -0.1 | -35.56 |
EBIT growth | 18.91 | 123.64 | -2.79 | -39.74 |
Net profit growth | 21.24 | 129.72 | -2 | -38.36 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 6,672.08 | 6,228.63 | 5,652.62 | 5,305.79 | 5,393.13 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 6,672.08 | 6,228.63 | 5,652.62 | 5,305.79 | 5,393.13 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 56.3 | 28.31 | 2.74 | 55.74 | 87.29 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,662.5 | 93.09 | 3,98,685.5 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,636 | 79.71 | 1,76,074.69 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,499.1 | 24.58 | 1,21,022.9 | 1,485.4 | 1.07 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,317.9 | 20.56 | 1,09,971.43 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,165.5 | 56.22 | 1,07,116.56 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & CEO
Chirayu R Amin
Director (Finance) & CFO
Rajkumar Baheti
Managing Director
Pranav Amin
Managing Director
Shaunak Amin
Independent Director
Ashok Barat
Company Sec. & Compli. Officer
Manisha Saraf
Independent Director
Jai S Diwanji
Independent Director
Manish Kejriwal
Independent Director
Geeta Goradia
Alembic Road,
Gujarat - 390003
Tel: 91-0265-2280550
Website: http://www.alembicpharmaceuticals.com/
Email: apl.investors@alembic.co.in
B-102&103 Shangrila,
Complex First Floor, Akota,
Vadodara - 390 020
Tel: 91-265-2356573/23567
Website: www.linkintime.co.in
Email: vadodara@linktime.co.in
Summary
Alembic Pharmaceuticals Limited manufactures and markets generic pharmaceutical products all over the world. The companys state of the art research and manufacturing facilities are approved by regulat...
Read More
Reports by Alembic Pharmaceuticals Ltd
What is the Alembic Pharmaceuticals Ltd share price today?
What is the Market Cap of Alembic Pharmaceuticals Ltd?
What is the PE and PB ratio of Alembic Pharmaceuticals Ltd?
What is the 52 Week High and Low of Alembic Pharmaceuticals Ltd?
What is the CAGR of Alembic Pharmaceuticals Ltd?
What is the shareholding pattern of Alembic Pharmaceuticals Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
